Histone Deacetylase 3 Deletion in Mesenchymal Progenitor Cells Hinders Long Bone Development

Marina Feigenson, Lomeli Carpio Shull, Earnest L. Taylor, Emily T. Camilleri, Scott M. Riester, Andre J van Wijnen, Elizabeth Bradley, Jennifer J Westendorf

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Long bone formation is a complex process that requires precise transcriptional control of gene expression programs in mesenchymal progenitor cells. Histone deacetylases (Hdacs) coordinate chromatin structure and gene expression by enzymatically removing acetyl groups from histones and other proteins. Hdac inhibitors are used clinically to manage mood disorders, cancers, and other conditions but are teratogenic to the developing skeleton and increase fracture risk in adults. In this study, the functions of Hdac3, one of the enzymes blocked by current Hdac inhibitor therapies, in skeletal mesenchymal progenitor cells were determined. Homozygous deletion of Hdac3 in Prrx1-expressing cells prevented limb lengthening, altered pathways associated with endochondral and intramembranous bone development, caused perinatal lethality, and slowed chondrocyte and osteoblast differentiation in vitro. Transcriptomic analysis revealed that Hdac3 regulates vastly different pathways in mesenchymal cells expressing the Prxx1-Cre driver than those expressing the Col2-CreERT driver. Notably, Fgf21 was elevated in Hdac3-CKOPrrx1 limbs as well as in chondrogenic cells exposed to Hdac3 inhibitors. Elevated expression of Mmp3 and Mmp10 transcripts was also observed. In conclusion, Hdac3 regulates distinct pathways in mesenchymal cell populations and is required for mesenchymal progenitor cell differentiation and long bone development.

Original languageEnglish (US)
Pages (from-to)2453-2465
Number of pages13
JournalJournal of Bone and Mineral Research
Volume32
Issue number12
DOIs
StatePublished - Dec 1 2017

Fingerprint

Bone Development
Mesenchymal Stromal Cells
Extremities
Gene Expression
Histone Deacetylases
Chondrocytes
Osteoblasts
Mood Disorders
Osteogenesis
Skeleton
Histones
Chromatin
Cell Differentiation
histone deacetylase 3
Enzymes
Population
Neoplasms
Proteins
Therapeutics

Keywords

  • CHONDROGENESIS
  • FGF21
  • HDAC3
  • LIMB DEVELOPMENT
  • MMP10
  • MMP3
  • RGFP966
  • VORINOSTAT

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Orthopedics and Sports Medicine

Cite this

Feigenson, M., Shull, L. C., Taylor, E. L., Camilleri, E. T., Riester, S. M., van Wijnen, A. J., ... Westendorf, J. J. (2017). Histone Deacetylase 3 Deletion in Mesenchymal Progenitor Cells Hinders Long Bone Development. Journal of Bone and Mineral Research, 32(12), 2453-2465. https://doi.org/10.1002/jbmr.3236

Histone Deacetylase 3 Deletion in Mesenchymal Progenitor Cells Hinders Long Bone Development. / Feigenson, Marina; Shull, Lomeli Carpio; Taylor, Earnest L.; Camilleri, Emily T.; Riester, Scott M.; van Wijnen, Andre J; Bradley, Elizabeth; Westendorf, Jennifer J.

In: Journal of Bone and Mineral Research, Vol. 32, No. 12, 01.12.2017, p. 2453-2465.

Research output: Contribution to journalArticle

Feigenson M, Shull LC, Taylor EL, Camilleri ET, Riester SM, van Wijnen AJ et al. Histone Deacetylase 3 Deletion in Mesenchymal Progenitor Cells Hinders Long Bone Development. Journal of Bone and Mineral Research. 2017 Dec 1;32(12):2453-2465. https://doi.org/10.1002/jbmr.3236
Feigenson, Marina ; Shull, Lomeli Carpio ; Taylor, Earnest L. ; Camilleri, Emily T. ; Riester, Scott M. ; van Wijnen, Andre J ; Bradley, Elizabeth ; Westendorf, Jennifer J. / Histone Deacetylase 3 Deletion in Mesenchymal Progenitor Cells Hinders Long Bone Development. In: Journal of Bone and Mineral Research. 2017 ; Vol. 32, No. 12. pp. 2453-2465.
@article{54498e4e33ae4bd29644c919f828b1dd,
title = "Histone Deacetylase 3 Deletion in Mesenchymal Progenitor Cells Hinders Long Bone Development",
abstract = "Long bone formation is a complex process that requires precise transcriptional control of gene expression programs in mesenchymal progenitor cells. Histone deacetylases (Hdacs) coordinate chromatin structure and gene expression by enzymatically removing acetyl groups from histones and other proteins. Hdac inhibitors are used clinically to manage mood disorders, cancers, and other conditions but are teratogenic to the developing skeleton and increase fracture risk in adults. In this study, the functions of Hdac3, one of the enzymes blocked by current Hdac inhibitor therapies, in skeletal mesenchymal progenitor cells were determined. Homozygous deletion of Hdac3 in Prrx1-expressing cells prevented limb lengthening, altered pathways associated with endochondral and intramembranous bone development, caused perinatal lethality, and slowed chondrocyte and osteoblast differentiation in vitro. Transcriptomic analysis revealed that Hdac3 regulates vastly different pathways in mesenchymal cells expressing the Prxx1-Cre driver than those expressing the Col2-CreERT driver. Notably, Fgf21 was elevated in Hdac3-CKOPrrx1 limbs as well as in chondrogenic cells exposed to Hdac3 inhibitors. Elevated expression of Mmp3 and Mmp10 transcripts was also observed. In conclusion, Hdac3 regulates distinct pathways in mesenchymal cell populations and is required for mesenchymal progenitor cell differentiation and long bone development.",
keywords = "CHONDROGENESIS, FGF21, HDAC3, LIMB DEVELOPMENT, MMP10, MMP3, RGFP966, VORINOSTAT",
author = "Marina Feigenson and Shull, {Lomeli Carpio} and Taylor, {Earnest L.} and Camilleri, {Emily T.} and Riester, {Scott M.} and {van Wijnen}, {Andre J} and Elizabeth Bradley and Westendorf, {Jennifer J}",
year = "2017",
month = "12",
day = "1",
doi = "10.1002/jbmr.3236",
language = "English (US)",
volume = "32",
pages = "2453--2465",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Histone Deacetylase 3 Deletion in Mesenchymal Progenitor Cells Hinders Long Bone Development

AU - Feigenson, Marina

AU - Shull, Lomeli Carpio

AU - Taylor, Earnest L.

AU - Camilleri, Emily T.

AU - Riester, Scott M.

AU - van Wijnen, Andre J

AU - Bradley, Elizabeth

AU - Westendorf, Jennifer J

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Long bone formation is a complex process that requires precise transcriptional control of gene expression programs in mesenchymal progenitor cells. Histone deacetylases (Hdacs) coordinate chromatin structure and gene expression by enzymatically removing acetyl groups from histones and other proteins. Hdac inhibitors are used clinically to manage mood disorders, cancers, and other conditions but are teratogenic to the developing skeleton and increase fracture risk in adults. In this study, the functions of Hdac3, one of the enzymes blocked by current Hdac inhibitor therapies, in skeletal mesenchymal progenitor cells were determined. Homozygous deletion of Hdac3 in Prrx1-expressing cells prevented limb lengthening, altered pathways associated with endochondral and intramembranous bone development, caused perinatal lethality, and slowed chondrocyte and osteoblast differentiation in vitro. Transcriptomic analysis revealed that Hdac3 regulates vastly different pathways in mesenchymal cells expressing the Prxx1-Cre driver than those expressing the Col2-CreERT driver. Notably, Fgf21 was elevated in Hdac3-CKOPrrx1 limbs as well as in chondrogenic cells exposed to Hdac3 inhibitors. Elevated expression of Mmp3 and Mmp10 transcripts was also observed. In conclusion, Hdac3 regulates distinct pathways in mesenchymal cell populations and is required for mesenchymal progenitor cell differentiation and long bone development.

AB - Long bone formation is a complex process that requires precise transcriptional control of gene expression programs in mesenchymal progenitor cells. Histone deacetylases (Hdacs) coordinate chromatin structure and gene expression by enzymatically removing acetyl groups from histones and other proteins. Hdac inhibitors are used clinically to manage mood disorders, cancers, and other conditions but are teratogenic to the developing skeleton and increase fracture risk in adults. In this study, the functions of Hdac3, one of the enzymes blocked by current Hdac inhibitor therapies, in skeletal mesenchymal progenitor cells were determined. Homozygous deletion of Hdac3 in Prrx1-expressing cells prevented limb lengthening, altered pathways associated with endochondral and intramembranous bone development, caused perinatal lethality, and slowed chondrocyte and osteoblast differentiation in vitro. Transcriptomic analysis revealed that Hdac3 regulates vastly different pathways in mesenchymal cells expressing the Prxx1-Cre driver than those expressing the Col2-CreERT driver. Notably, Fgf21 was elevated in Hdac3-CKOPrrx1 limbs as well as in chondrogenic cells exposed to Hdac3 inhibitors. Elevated expression of Mmp3 and Mmp10 transcripts was also observed. In conclusion, Hdac3 regulates distinct pathways in mesenchymal cell populations and is required for mesenchymal progenitor cell differentiation and long bone development.

KW - CHONDROGENESIS

KW - FGF21

KW - HDAC3

KW - LIMB DEVELOPMENT

KW - MMP10

KW - MMP3

KW - RGFP966

KW - VORINOSTAT

UR - http://www.scopus.com/inward/record.url?scp=85037997557&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037997557&partnerID=8YFLogxK

U2 - 10.1002/jbmr.3236

DO - 10.1002/jbmr.3236

M3 - Article

C2 - 28782836

AN - SCOPUS:85037997557

VL - 32

SP - 2453

EP - 2465

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - 12

ER -